Table 2

Patients characteristics and disease activity responses classified according to presence of anti-cyclic citrullinated protein (CCP) and rheumatoid factor (RF)

Anti-CCP and RF both negative (N = 26)Either anti-CCP or RF positive (N = 24)Anti-CCP and RF both positive (N = 68)p Value*
Mean (SD) age, years31.9 (3.6)33.5 (4.1)32.2 (3.5)0.35
Disease duration median, months8356570.03†
DAS28 CRP 3>3.2 at first trimester, % (n/N)62 (16/26)29 (7/24)72 (49/68)0.95
Prednisone use during pregnancy, % (n/N)27 (7/26)46 (11/24)44 (29/66)0.11
Sulfasalazine use during pregnancy, % (n/N)35 (9/26)25 (6/24)36 (24/66)0.90
Responders‡ during pregnancy, % (n/N)75 (12/16)14 (1/7)43 (21/49)0.01†
Flare§ post partum, % (n/N)42 (11/26)33 (8/24)34 (23/68)0.42
  • *Anti-CCP and RF “both negative” versus combined groups of “either/or” and “both positive” (ANOVA, χ2 or Fisher exact test); †p = <0.05; ‡moderate and good responders combined; analysis is restricted to patients with DAS28 CRP 3>3.2 in the first trimester, n = 72; §“moderate and severe” flare post partum combined.

  • ANOVA, analysis of variance; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score.